Vasopressin and terlipressin as first-line therapy in fulminant ovine septic shock

Vasopressinergic V1 receptor agonists, such as arginine vasopressin (AVP) and terlipressin (TP), are increasingly used to stabilize haemodynamics in catecholamine-refractory hyperdynamic septic shock [1]. In the current sepsis guidelines, however, norepinephrine (NE) and dopamine are still recommended as vasopressors of choice [2]. The present study was designed as a prospective, randomized, controlled laboratory experiment to elucidate the effects of AVP and TP (when given as first-line therapy) on mesenteric blood flow (Qma) and mortality in an established model of ovine septic shock.